{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Seven participants were assigned nab-paclitaxel in dose of 25mg/m\\^2. Five participants were assigned nab-paclitaxel in dose of 20mg/m\\^2.","groups":[{"description":"Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy\n\nCetuximab: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor\n\nCisplatin: Cisplatin is an anti-cancer chemotherapy drug\n\nNab-Paclitaxel: paclitaxel albumin-stabilized nanoparticle formulation\n\nintensity-modulated radiation therapy: intensity-modulated radiation therapy","id":"OG000","title":"Phase I Nab-Paclitaxel, Cisplatin, Cetuximab and Radiotherapy"}],"paramType":"NUMBER","populationDescription":"12 patients enrolled in the phase I study.","reportingStatus":"POSTED","timeFrame":"90 days","title":"Phase I Maximum Tolerated Dose of Nab-Paclitaxel","type":"PRIMARY","unitOfMeasure":"mg/m^2"}